Nanoparticle biointerfacing by platelet membrane cloaking

Summary

This study transfers the complex biological interface of human platelets onto polymeric nanoparticles for disease-targeted drug delivery. The investigators enclosed synthetic cores in a right-side-out, single-layer platelet membrane carrying native adhesion and immunomodulatory proteins. Relative to uncoated particles, the cloaked nanoparticles were taken up less by macrophage-like cells and did not trigger particle-associated complement activation in autologous human plasma. They also reproduced platelet-like binding to damaged human and rodent blood vessels and to pathogens that naturally adhere to platelets. Functional delivery was tested in two preclinical settings: docetaxel treatment in a rat model of coronary restenosis and vancomycin treatment in a mouse model of systemic bacterial infection. In each, the platelet-mimetic carrier enhanced therapeutic efficacy. The principal result is a single biological coating that integrates immune evasion and multivalent disease recognition across vascular injury and infection. However, the abstract does not give particle dose, circulation, targeting, drug exposure, efficacy effect sizes, sample numbers, or toxicity. The two animal models use different cargos and cannot establish broad generality. Human plasma testing addresses complement only, while thrombosis risk, platelet activation, repeated dosing, membrane sourcing, pathogen safety, manufacturing, and clinical efficacy remain unresolved.